MAP1S and metastatic malignant neoplasm in the lymph nodes: However, patients with G3 tumors (Figure 4A), with lymph node metastasis (Figure 4B), with distant metastasis (Figure 4C), with stage III and IV disease (Figure 4D) and with survival shorter than 65 months (Figure 4E) had significantly lower levels of MAP1S than those with G1 and G2 tumor grades, without lymph node metastasis and distant metastasis, with stage I and II, and with a survival longer than 65 months (Table 2).